1 / 21

Public Private collaborations to optimise translational research and pathways to patients: IMI

Public Private collaborations to optimise translational research and pathways to patients: IMI. Magda Chlebus, Director Science Policy Warsaw, 22 May 2015. EFPIA.

jeffery
Télécharger la présentation

Public Private collaborations to optimise translational research and pathways to patients: IMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Public Private collaborations to optimise translational research and pathways to patients: IMI Magda Chlebus, Director Science Policy Warsaw, 22 May 2015

  2. EFPIA Aim of the European Federation of Pharmaceutical Industries & Associations is to promote pharmaceutical discovery and development in Europe and to bring to the market medicinal products in order to improve human health worldwide. EFPIA’s represents the pharmaceutical industry operating in Europe. Its direct membership includes 33 national associations and 41 leading companies. Two specialised groups within EFPIA represent vaccine manufacturers – Vaccines Europe, with 17 member companies) and European / emerging bio-pharmaceutical companies – EBE with +/- 50 member companies. “Partners in Research” is constituted of non-pharma companies that collaborate in the IMI public-private membership. This constituent entity, created in June 2014, counts 5 members. EFPIA - December 2014

  3. Evolution: science and technology Science more exciting and promising than ever More diverse R&D toolbox Life science integrates more disciplines every day

  4. Evolution: the industry (-ies?) From vertical integration to externalisation and open collaboration From market access to patient access and outcomes From products to therapies From pharma only/mainly to ecosystems where we do not always hold the keys of success

  5. Elias A. Zerhouni, President Global R&D, SanofiEditorial in Science Translational Medicine, January 2014 ‘We must acknowledge that no single institution, company, university, country, or government has a monopoly on innovation.’

  6. HUMAN & ANIMAL

  7. Complementaryinvestments: NIH and private sector in biomedical research U.S. Private Sector: $51 B Product Clinical research Translational research Basic Research Idea National Institutes of Health: $31 B Tufts Center for the Study of Drug Development, Jan, 2015

  8. IMI – Europe’s partnership for health €2.5 bn €2.5 bn > €5 bn Partnership 2008 - 2024

  9. Essential features for research and policy agendas • Public private partnership • Companies and public partners work together • Industry cost is not reimbursed: it is our in kind contribution • Public partners (including companies up to 500 mio turnover) cost is reimbursed by EU: grants for collaborating with industry • Industry defines the research agenda and projects • Beyond the shelf – impact on research, regulatory and medical practice • Managed by a neutral broker that allows participation of authorities and patients • “Institutionalized” – legitimacy of direction and outputs

  10. IMI2 Strategic Research Agenda

  11. Strategic Research Agenda: reduced attrition, faster patient access, improved outcomes !!

  12. First five big themes Differentiating Enablers for all themes Towards early and effective patient access to innovative prevention and treatment solutions (MAPPs): Target validation based on human biology Stratified medicine, precision medicine Innovation in clinical trials Data generation and interpretation (knowledge management) Prevention, disease interception, patient adherence (incl. societal acceptance of vaccines) Effect on medical practice and outcomes (health/disease management) Regulatory framework (including pharmacovigilance) Patient access  Therapeutic Areas and Cross-cutting Themes • Neuro-degeneration Successfully prevent and treat dementia and other neurodegenerative diseases • Prevention and treatment of immune-mediated diseaseAdvance immunological understanding to deliver new medicines and new and better vaccines • Metabolic disorders Tackle all phases of disease and its complications, including prevention and early interception • Infection control Address big societal problem related to multidrug resistance and develop new and better vaccines • Translational Safety Development of new human biology platform to predict toxicity and safety during early drug development

  13. New Big Challenges under consideration Real World Evidence and for Better Outcomes Advanced Therapies “industrialisation” Biomarker Strategy One Health Title of the powerpoint

  14. Typical IMI project life cycle Stage 1 Stage 2 Topic definition phase Negotiation phase Industry consortium Academic research teams Hospitals Applicant consortium Mid-size enterprises Regulators Signature of Project Agreement and Grant Agreement Identification of topics and willingness to collaborate by industry partners industry consortium SMEs Patients’ organisations Submission of proposals by public consortia & evaluation by independent experts Preparation of full proposal & evaluation by independent experts/ethical panel Project launch!

  15. An international, cross-sector community Over 7 000 researchers 59 public-private consortia

  16. Programme across products lifecycle New Drugs for Bad Bugs programme Topic 1: COMBACTE a) CT networks and CT design b) Clinical Development of Antibiotics Topic 2 : TRANSLOCATION Research penetration and efflux Gram-negatives Data Hub and Learning from R&D experience Topic 3 : ENABLEDiscovery & development of new drugs combatting Gram–negative infections Topic 4: DRIVE AB Driving re-investment in R&D and Responsible use of Antibiotics Topic 5: Clinical development of antibacterial agents for Gram-negative antibiotic resistant pathogens Topic 6: Systemic Antibacterials against hospital acquired infections Topic 7: Inhalational Antibacterials in Cystic Fibrosis and COPD DEVELOPMENT CT NETWORKS DISCOVERY ACCESS DEVELOPMNENT CT NETWORKS ND4BB Information Centre – All data generated is submitted and is accessible to all consortium partners

  17. It works! IMI delivers on Innovation and Health - a few examples: • Established robust validated models for Alzheimer, Diabetes, Schizophrenia, Asthma • Developed clinically relevant biomarkers for Alzheimer, Diabetes, Schizophrenia, Asthma • Established robust tools for drug safety prediction, prevention and monitoring • Establishment and regulatory submission of key standards and tools for drug development in infectious diseases, COPD, diabetes • Improved clinical trial design (shorter/smaller trials) and process in schizophrenia, pain, autism • Co-funding of antibiotics and vaccines development • Projects launched and planned on use of real life data and alignment of regulators and payers data requirement • Uptake by Regulators has started (guidance, biomarkers)

  18. IMI2 vision: European Partnership for Health Addressing healthcare priorities identified by the WHO 2013 report   Strategic Research Agenda aimed at progressing the vision of stratified medicines: prevention, treatment and health management Entire product cycle from discovery, through development to healthcare delivery and access models Collaboration across sectors to harness all knowledge and technologies which can contribute to IMI2 vision - diagnostics, imaging, IT, medical devices, …

  19. Need more information? EFPIA Science Policy Team Mail: science-policy@efpia.eu IMI office Mail: information@imi.europa.eu National Contact Point

More Related